A trial is recruiting adults with type 2 diabetes and diabetic kidney disease to investigate an injection into the kidney that could potentially preserve kidney function. The drug has already shown promising results in a phase 2 study, especially in participants with the highest risk of kidney failure.

Multiple clinical trials are recruiting participants to see how well the investigational drug orforglipron can improve blood glucose levels and reduce body weight.  

Current clinical trials for people with type 1 diabetes are exploring treatments to restore beta cell function, prevent and treat complications, and reduce the burden of blood sugar management. See if you're eligible to enroll.

The study is investigating whether an injectable drug, ZT-01, could prevent nighttime hypoglycemia in people with type 1 diabetes. Participate and shape the future of diabetes care.

Advances in blood glucose management, weight loss, and kidney health are at the forefront of type 2 diabetes research. Here are several exciting type 2 diabetes trials that are actively recruiting.

Clinical researchers are working to discover new strategies and medications to help children with diabetes live healthier, happier lives. Here are some exciting clinical trials your child might be able to join now.

Children with type 1 diabetes under the age of 6 may be eligible to participate in a trial testing dasiglucagon (Zegalogue) as a rescue therapy for low blood glucose.

Key takeaways:

• Fully closed-loop automated insulin delivery (AID) systems can simplify diabetes management by eliminating the need for meal announcements.
• Two recent studies presented at the ATTD 2025 conference showed these systems can effectively regulate glucose levels.
• Researchers said more work is needed to improve the results with the systems, including reducing mealtime spikes.

Key takeaways: 

• Many people with diabetes struggle to manage mealtime blood sugar levels, even with new advances in technology.
• In a recent clinical trial of adults with type 1 diabetes, the inhaled insulin Afrezza delivered similar A1C reductions compared to usual care, including multiple daily injections and automated insulin delivery.
• Experts emphasized that inhaled insulin is not a one size fits all approach – some trial participants did well on Afrezza, while others did not.

Key takeaways:

• Finerenone (brand name Kerendia) is an oral medication approved for people with chronic kidney disease and type 2 diabetes.
• New research shows that finerenone also reduces the risk of new-onset diabetes in people with heart failure.
• This promising data suggests that finerenone will likely be approved for heart failure and reducing type 2 diabetes risk in the future.

Key takeaways:

• People with type 2 diabetes and chronic kidney disease (CKD) who took Ozempic (semaglutide) slowed the progression of kidney disease by 24% and cut their risk of death from kidney disease.
• Patients who took Ozempic versus placebo also cut their risk of major heart problems by 18%.
• The latest: Newly FDA approved for CKD, Ozempic is the first GLP-1 drug that’s been approved to reduce the progression of kidney disease and risk of cardiovascular events in adults with type 2 diabetes.

Key takeaways:

• Fully closed loop systems take automated insulin delivery a step further by skipping meal announcements.
• People with diabetes in the open source community are using fully closed loop systems, and diabetes technology makers are developing and testing these systems for future submission to the FDA.
• People who have used fully closed loop systems say they reduce the burden of daily diabetes management.

Key takeaways: 

• Many people with diabetes struggle to manage mealtime blood sugar levels, even with new advances in technology.
• In a recent clinical trial of adults with type 1 diabetes, the inhaled insulin Afrezza delivered similar A1C reductions compared to usual care, including multiple daily injections and automated insulin delivery.
• Experts emphasized that inhaled insulin is not a one size fits all approach – some trial participants did well on Afrezza, while others did not.

Key takeaways:

• Finerenone (brand name Kerendia) is an oral medication approved for people with chronic kidney disease and type 2 diabetes.
• New research shows that finerenone also reduces the risk of new-onset diabetes in people with heart failure.
• This promising data suggests that finerenone will likely be approved for heart failure and reducing type 2 diabetes risk in the future.

Key takeaways:

• People with type 2 diabetes and chronic kidney disease (CKD) who took Ozempic (semaglutide) slowed the progression of kidney disease by 24% and cut their risk of death from kidney disease.
• Patients who took Ozempic versus placebo also cut their risk of major heart problems by 18%.
• The latest: Newly FDA approved for CKD, Ozempic is the first GLP-1 drug that’s been approved to reduce the progression of kidney disease and risk of cardiovascular events in adults with type 2 diabetes.

Key takeaways:

• People with diabetes-related complications can benefit significantly from incorporating technology to improve and reduce time spent managing blood sugar levels.
• Tools like voice assistants and AI can help reduce the burden of some complications.
• Technology can also be a burden, and one size does not fit all.

Key takeaways:

• CGM use for people with type 2 diabetes led to significant improvements in glucose control and reduced hospitalization.
• Automated insulin delivery device use was shown to improve time in range, lower A1C, and reduce missed work for parents and school for kids.
• Tighter targets led some AID users to see better time in range and less time experiencing low blood sugar.

Key takeaways:

• The Medtronic MiniMed 780G AID system automatically adjusts insulin doses from an insulin pump every five minutes based on CGM readings.
• Abbott will make a specific CGM sensor for the Medtronic Minimed 780G. Medtronic also announced its new CGM sensor, the Simplera, has been approved by the FDA. The Simplera is half the size of the current sensor.
• The latest: Newly presented clinical evidence positions Medtronic to expand access to the 780G system to those with type 1 aged 2-6 as well as those with type 2 diabetes.

Key takeaways:

• VX-880 is an investigational islet cell therapy by Vertex that shows promise as a functional “cure” for type 1 diabetes.
• New data shows that study participants experienced significant improvements in A1C, glucose control, and a reduced need for insulin.
• The VX-880 trial was put on hold earlier in 2024 due to two participant deaths. The deaths are now believed to be unrelated to the study drug.

Key takeaways:

• The FDA has issued a warning to users of continuous glucose monitors after reports of missed urgent blood sugar alarms on smartphones.
• Free apps can act as a backup for CGM alerts on your phone.
• A secondary alert system, like a CGM receiver or the SugarPixel standalone display, can ensure critical alerts are noticed.

The FDA has approved Susvimo, which delivers medicine continuously via a surgical implant that can be refilled every six months vs. getting monthly injections.

Key takeaways:

• Abbott's FreeStyle Libre 2 and 3 continuous glucose monitors no longer need to be removed for imaging tests. 
• CGM readings during an MRI may be affected for up to an hour after the procedure.
• While reducing the burden of removing a CGM sensor, users still need to monitor their blood sugar levels and may need to use a glucometer.

• The Lingo is an over-the-counter continuous glucose monitor for people without diabetes who want to improve their metabolic health. 
• The Libre Rio is a CGM for adults with type 2 who do not use insulin to manage their diabetes. 
• Both sensors are based on Abbott’s FreeStyle Libre technology and have the same shape and size as the Freestyle Libre 2 and Libre 3 sensors. 

Key takeaways:

• Zepbound, a new weight loss drug, targets two key hormone receptors (GIP and GLP-1) to help reduce excess weight.
• Mounjaro and Zepbound (generic name tirzepatide) are approved to treat several type 2 diabetes and weight loss, respectively.
• The latest: Eli Lilly, the maker of Zepbound, recently announced that the two lowest doses of the drug will be available at a reduced cost of $400 and $550 and won't be covered by insurance.

Key takeaways: 

• The FDA issued an alert to healthcare providers, compound pharmacies, and patients about recent overdoses associated with compounded injectable semaglutide, leading to the dosing of five to 20 times more than the intended amount of semaglutide.
• To prevent challenges with dosing errors and overdoses, the FDA encourages patients to talk to healthcare providers to clarify how to measure and administer correct doses with a syringe. 
• The FDA had previously issued a warning urging people to avoid off-brand or compounded formulations of the popular semaglutide medications Ozempic, Wegovy, and Rybelsus. 

Approval for Novo Nordisk’s much-anticipated once-weekly insulin has been denied at this time by the U.S. Food and Drug Administration. The medication has been approved in Europe, Canada, Australia, Japan, and China.